• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Toric IOLs effectively correct some types of irregular astigmatism

News
Article

The angled bow-tie pattern of astigmatism was corrected more accurately compared with the asymmetric bow-tie pattern of astigmatism

(Image Credit: AdobeStock/Oktay)

(Image Credit: AdobeStock/Oktay)

Implantation of toric intraocular lenses (IOLs) effectively corrects specific types of irregular corneal astigmatism in patients undergoing cataract surgery. The angled bow-tie pattern of astigmatism was corrected more accurately compared with the asymmetric bow-tie pattern of astigmatism,1 according to first author Xiteng Chen, MD. She is from the Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital, Tianjin, China.

Chen and associates emphasized the importance of eliminating as much residual astigmatism as possible after cataract surgery to obtain the best visual acuity (VA) without glare, monocular diplopia, and visual distortion. Toric IOLs have been widely adopted as an effective and dependable solution for patients with regular corneal astigmatism.2,3 However, the corrective effect of toric IOLs for irregular corneal astigmatism needs to be determined.

The investigators conducted a retrospective cohort study to observe the corrections obtained following the implantation of toric IOLs for specific types of irregular corneal astigmatism. The study included 34 with either the asymmetric bow-tie pattern of astigmatism (type I) or the angled bow-tie pattern (type II). The investigators compared the changes in the preoperative corneal astigmatism, VA, manifest refraction, and objective visual quality between the 2 groups.

Chen and colleagues reported that the average uncorrected distance VA improved significantly from 0.86 ± 0.40 logarithm of the minimum angle of resolution (logMAR) to 0.22 ± 0.15 logMAR and the preoperative corneal astigmatism of 2.05 ± 0.90 diopters (D) improved to 0.78 ± 0.57 D (P < 0.001 for both comparisons), with 32% of eyes within 0.50 D.

A comparison of the 2 groups showed that the residual astigmatism prediction errors of the type I and type II cases were 0.97 ± 0.68 D and 0.66 ± 0.37 D, respectively (P = 0.100). The mean spherical equivalent prediction error in the type II cases was significantly smaller than that in type I cases (0.07 ± 0.36 D and − 0.29 ± 0.52 D, respectively) (P = 0.030).

The authors concluded, “The toric IOL effectively corrected specific types of irregular corneal astigmatism in cataract surgery. The eyes with the angled bow-tie pattern showed higher accuracy in refractive predictions compared to the eyes with the asymmetric bow-tie pattern.

References:
  1. Chen X, Jiang Y, Gao N, et al. Effectiveness of toric intraocular lens implantation for correcting irregular corneal astigmatism in cataract eyes. Sci Rep. 2024;14: 8868; https://doi.org/10.1038/s41598-024-59303-0
  2. Mencucci R, Giordano C, Favuzza F, et al.Astigmatism correction with toric intraocular lenses: Wavefront aberrometry and quality of life. Br J Ophthalmol. 2023;97:578–582; https://doi.org/10.1136/bjophthalmol-2013-303094
  3. Thomas BC, Khoramnia R, Auffarth GU, Holzer MP. Clinical outcomes after implantation of a toric intraocular lens with a transitional conic toric surface. Br J Ophthalmol. 2018;102:313–316; https://doi.org/10.1136/bjophthalmol-2017-310386
Related Videos
EyeCon Co-chair Oluwatosin U. Smith, MD: Passion for Research and Education Drives Her Commitment to Ophthalmology
Video 3 - "Approaching Asymptomatic Cases with Risk Factors"
Video 2 - "Do Dry Eye Diagnostics Change the Management of Dry Eye?"
Dr. SriniVas Sadda Discusses Vision for ARVO as New President: Collaboration, Funding Challenges, and Impact of Annual Meetings
Deb Ristvedt, DO's CIME 2024 Talk Highlights Innovations in Treating Glaucoma via the Trabecular Meshwork
Dr. Inder Paul Singh's Insights: Improving Glaucoma Outcomes with Early Intervention and Reduced Medication
CIME 2024: Kelsey Roelofs, MD, details collaborative strategies for the management of thyroid eye disease
CIME 2024: Diagnostic tips and treatments for managing Demodex blepharitis
© 2024 MJH Life Sciences

All rights reserved.